| Characteristic | Preclinical | Phase I | Phase II | Phase III | Pre-registration |
|---|---|---|---|---|---|
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Region
Worldwide
Survey time period
Q4 2021 to Q4 2025
Supplementary notes
The source defines gene therapies as including the following: gene therapy; cellular therapy, chimeric antigen receptor; cellular therapy, T cell receptor; lytic virus.
Citation formats









